bevacizumab
Selected indexed studies
- Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook. (Cancer Treat Rev, 2020) [PMID:32335505]
- Optimal bevacizumab treatment strategy in advanced ovarian cancer: A review. (Cancer Treat Rev, 2025) [PMID:40349571]
- SB8: A Bevacizumab Biosimilar. (Target Oncol, 2020) [PMID:33206282]
_Worker-drafted node — pending editorial review._
Connections
bevacizumab is a side effect of
Sources
- Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook. (2020) pubmed
- Optimal bevacizumab treatment strategy in advanced ovarian cancer: A review. (2025) pubmed
- SB8: A Bevacizumab Biosimilar. (2020) pubmed
- MYL-1402O: A Bevacizumab Biosimilar. (2022) pubmed
- Adjuvant Intralesional Bevacizumab in Pediatric and Adult Populations With Recurrent Respiratory Papillomatosis: A Systematic Review. (2024) pubmed
- Bevacizumab-induced hypertension: Clinical presentation and molecular understanding. (2018) pubmed
- The discovery of Bevacizumab. An historical reappraisal. (2025) pubmed
- Systemic Bevacizumab for Treatment of Respiratory Papillomatosis: International Consensus Statement. (2021) pubmed
- Bevacizumab in Cervical Cancer: 5 Years After. (2018) pubmed
- Bevacizumab-induced subungual hemorrhage. (2024) pubmed